The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development
Open Access
- 24 November 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (22) , 5785-5796
Abstract
Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII inhibitors is essential for risk identification and the design of novel strategies to prevent inhibitor development. The Hemophilia Inhibitor Previously Untreated Patients (PUPs) Study (HIPS; www.clinicaltrials.gov #NCT01652027) is the first prospective cohort study to evaluate comprehensive changes in the immune system during the first 50 exposure days (EDs) to FVIII in patients with severe hemophilia A. HIPS participants were enrolled prior to their first exposure to FVIII or blood products (“true PUPs”) and were evaluated for different immunological and clinical parameters at specified time points during their first 50 EDs to a single source of recombinant FVIII. Longitudinal antibody data resulting from this study indicate that there are 4 subgroups of patients expressing distinct signatures of FVIII-binding antibodies. Subgroup 1 did not develop any detectable FVIII-binding immunoglobulin G (IgG) antibodies. Subgroup 2 developed nonneutralizing, FVIII-binding IgG1 antibodies, but other FVIII-binding IgG subclasses were not observed. Subgroup 3 developed transient FVIII inhibitors associated with FVIII-binding IgG1 antibodies, similar to subgroup 2. Subgroup 4 developed persistent FVIII inhibitors associated with an initial development of high-affinity, FVIII-binding IgG1 antibodies, followed by IgG3 and IgG4 antibodies. Appearance of FVIII-binding IgG3 was always associated with persistent FVIII inhibitors and the subsequent development of FVIII-binding IgG4. Some of the antibody signatures identified in HIPS could serve as candidates for early biomarkers of FVIII inhibitor development.Keywords
This publication has 35 references indexed in Scilit:
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsBlood, 2013
- Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection databaseHaemophilia, 2012
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Plasma cell development: From B-cell subsets to long-term survival nichesSeminars in Immunology, 2008
- Deconvolution of antibody affinities and concentrations by non-linear regression analysis of competitive ELISA dataJournal of Immunological Methods, 2007
- European Study on Orthopaedic Status of haemophilia patients with inhibitorsHaemophilia, 2007
- Regulation of plasma-cell developmentNature Reviews Immunology, 2005
- Inhibitors in hemophilia ABlood Coagulation & Fibrinolysis, 2004
- New Characteristics of Anti-Factor VIII Inhibitor Antibody Epitopes and Unusual Immune Responses to Factor VIIISeminars in Thrombosis and Hemostasis, 2002
- High incidence of anti‐FVIII antibodies against non‐coagulant epitopes in haemophilia A patients: a possible role for the half‐life of transfused FVIIIBritish Journal of Haematology, 1996